Cited by 285Cytokine Signaling Pathways and InteractionsCancer-related Molecular PathwaysSignaling Pathways in Disease

Cyclin D1 Is Transcriptionally Regulated by and Required for Transformation by Activated Signal Transducer and Activator of Transcription 3

Open access
Leslie, Kenneth, Lang, Cynthia, Devgan, Geeta, Azare, Janeen, Berishaj, Marjan, Gerald, William, Kim, Young Bae, Paz, Keren +5 more·2006·Cancer Research

Abstract

Signal transducers and activators of transcription 3 (STAT3) is a transcription factor that is aberrantly activated in many cancer cells. Constitutively activated STAT3 is oncogenic, presumably as a consequence of the genes that it differentially regulates. Activated STAT3 correlated with elevated cyclin D1 protein in primary breast tumors and breast cancer–derived cell lines. Cyclin D1 mRNA levels were increased in primary rat-, mouse-, and human-derived cell lines expressing either the oncogenic variant of STAT3 (STAT3-C) or vSrc, which constitutively phosphorylates STAT3. Mutagenesis of STAT3 binding sites within the cyclin D1 promoter and chromatin immunoprecipitation studies showed an association between STAT3 and the transcriptional regulation of the human cyclin D1 gene. Introduction of STAT3-C and vSrc into immortalized cyclin D1−/− and cyclin D1−/+ fibroblasts led to anchorage-independent growth of only cyclin D1−/+ cells. Furthermore, knockdown of cyclin D1 in breast carcinoma cells led to a reduction in anchorage-independent growth. Phosphorylation of the retinoblastoma (Rb) protein [a target of the cyclin D1/cyclin-dependent kinase 4/6 (cdk4/6) holoenzyme] was delayed in the cyclin D1−/− cells relative to cyclin D1−/+ cells. The E7 oncogene, whose activity includes degradation of Rb and dissociation of Rb from E2F, did not confer anchorage-independent growth to the cyclin D1−/− cells but, in conjunction with vSrc, resulted in robust growth in soft agar. These results suggest both a cdk-dependent and cdk-independent role for cyclin D1 in modulating transformation by different oncogenes. (Cancer Res 2006; 66(5): 2544-52)

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-05-2203

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • IL-6 interacts with the receptor JAK to induce STAT-3 activation, which activates oncogenes such as MCL-1 and upregulates proliferation genes such as Cyclin-D1, resulting in cancer cell proliferation.

    “IL-6 plays a significant role in inducing tumor growth as it interacts with the receptor, JAK, to induce STAT-3 activation. STAT-3 then activates oncogenes such as MCL-1 (29) and upregulates genes involved in proliferation such as Cyclin-D1 (30). These activities result in the induction of cancer cell proliferation.”
  • The STAT3 target CCND1, encoding cyclin D1, is upregulated transcriptionally by active STAT3 and is required for STAT3-mediated transformation.

    “A critical mediator of cell growth downstream of STAT3 is its target CCND1, encoding gene cyclin D1, which is upregulated transcriptionally by active STAT3 and is required for STAT3-mediated transformation.74”

The citation lists haven’t been fetched yet

References 57 · Cited by 285

Authors
Leslie, K., Lang, C., Devgan, G., Azare, J., Berishaj, M., Gerald, W., Kim, Y. B., Paz, K., Darnell, J. E., Albanese, C., Sakamaki, T., Pestell, R., & Bromberg, J.
Affiliations
  • 1Medicine and Departments of
  • Memorial Sloan Kettering Cancer Center (US)
  • Rockefeller University (US)
  • 3The Rockefeller University, New York, New York; and
  • Georgetown University (US)
Venue
Cancer Research
Published
2006-03-01
Volume
66
Issue
5
Pages
2544-2552
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2107398189
Cited by
285
References
57
Citations by year
2026: 9 · 2025: 20 · 2024: 12 · 2023: 14 · 2022: 17 · 2021: 17 · 2020: 16 · 2019: 13 · 2018: 7 · 2017: 17 · 2016: 11 · 2015: 8 · 2014: 16 · 2013: 17 · 2012: 15
FWCI
8.41
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Breast Cancer Alliance
  • National Institutes of Health
  • National Cancer Institute (R01CA087637, R01 CA87637)
Topics
  • Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
Keywords
cyclin D1, STAT3, transcriptional regulation, oncogenic transformation, breast cancer, retinoblastoma protein phosphorylation, CDK4/6, anchorage-independent growth, E7 oncogene
MeSH terms
Animals, Binding Sites, Breast Neoplasms, Cell Adhesion, Cell Transformation, Neoplastic, Humans, Luciferases, Promoter Regions, Genetic, RNA, Messenger, Transcriptional Activation, G1 Phase, Mutagenesis, Site-Directed, Cyclin D1, RNA, Small Interfering, NIH 3T3 Cells, Cell Line, Tumor, Cell Growth Processes, Papillomavirus E7 Proteins, STAT3 Transcription Factor, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review